Mather Group’s ANI Pharmaceuticals ANIP Stock Holding History

Mather Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.25K	Hold	31	–	–	﹤0.01%	2021
2026 Q2	$2.57K	Hold	31	–	–	﹤0.01%	1707
2026 Q1	$2.38K	Buy	+31	New	+$2.42K	﹤0.01%	1677
2025 Q4	–	Sell	-31	Closed	-$2.84K	–	689
2025 Q3	$2.84K	Buy	+31	New	+$2.53K	﹤0.01%	1492
2025 Q2	–	Sell	-31	Closed	-$2.08K	–	659
2025 Q1	$2.08K	Hold	31	–	–	﹤0.01%	1565
2024 Q4	$1.71K	Hold	31	–	–	﹤0.01%	1560
2024 Q3	$1.85K	Hold	31	–	–	﹤0.01%	1497
2024 Q2	$2.14K	Hold	31	–	–	﹤0.01%	1872
2024 Q1	$1.71K	Buy	+31	New	+$1.87K	﹤0.01%	1568

Other funds holding ANIP

Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Quadrant Capital Group Cincinnati, Ohio $3.7B AUM 33.76% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Mather Group's ANIP Position: Q3 2026 in Review

Mather Group held its ANI Pharmaceuticals (ANIP) position steady in Q3 2026 at 31 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2021.

Mather Group first reported a position in ANIP in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.84K in Q3 2025. 24 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

Mather Group held 31 shares of ANI Pharmaceuticals worth $2.25K as of Q3 2026.
Mather Group left its ANI Pharmaceuticals share count unchanged in Q3 2026.
ANI Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #2021 holding.
Mather Group first reported a position in ANI Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Mather Group's ANI Pharmaceuticals position peaked at $2.84K in Q3 2025.
24 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.